Avacincaptad Pegol 减缓地图样萎缩眼的椭圆体带进行性降解与丢失
该研究为 GATHER 1 和 GATHER 2 试验的事后分析,纳入 292 只接受 ACP 2 mg 治疗眼和 332 只假治疗眼,评估基线椭圆体带(EZ)指标与地图样萎缩(GA)进展及光感受器丢失的关联。结果显示基线 EZ 衰减越高,GA 增长和 EZ 丢失越快;ACP 2 mg 在 12 个月内显著减少 EZ 总衰减增长 19.5%(P = .0009)和部分 EZ 衰减百分比增长 55.3%(P < .0001)。
要点
- 基线 EZ 总衰减和部分衰减越高,GA 增长和 EZ 丢失越快
- ACP 2 mg 在 12 个月内减少 EZ 总衰减增长 19.5%
- ACP 2 mg 在 12 个月内减少部分 EZ 衰减百分比增长 55.3%
核心结论
- 基线 EZ 总衰减和部分衰减越高,GA 增长和 EZ 进行性丢失越快,提示 EZ 指标可预测未来 GA 增长和光感受器丢失。
- ACP 2 mg 在 12 个月内较假治疗显著减少 EZ 丢失和降解。
研究设计与样本
- GATHER 1(II/III 期)和 GATHER 2(III 期)试验的事后分析。
- 纳入 50 岁及以上、研究眼为非中心点受累 GA 的患者,共 292 只眼接受 ACP 2 mg、332 只眼接受假治疗。
- 采用谱域 OCT 多层分割并经认证阅片者验证,测量 EZ 总衰减或丢失(EZ-RPE 厚度 0 μm)和部分 EZ 衰减或降解(EZ-RPE 厚度 ≤ 20 μm)。
- 通过眼底自发荧光评估 GA 病灶增长。
主要发现
- 假治疗眼中,基线 EZ 总衰减和部分衰减较高四分位组的 12 个月 GA 增长和 EZ 总衰减进展显著更大。
- ACP 2 mg 较假治疗在 12 个月内显著减少 EZ 总衰减平均增长 19.5%(P = .0009)。
- ACP 2 mg 较假治疗在 12 个月内显著减少部分 EZ 衰减百分比平均增长 55.3%(P < .0001)。
关键数值与推荐
- EZ 总丢失定义为 EZ-RPE 厚度 0 μm。
- 部分 EZ 衰减或降解定义为 EZ-RPE 厚度 ≤ 20 μm。
临床怎么用
- EZ 指标可用于识别 GA 进展高风险患者,以考虑早期治疗干预。
- ACP 治疗可减缓 GA 患者 EZ 丢失和降解,支持其用于保护光感受器结构。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ellipsoid zone (EZ) integrity is a key biomarker and surrogate for photoreceptor health, including in age-related macular degeneration. The objectives of this study were to determine (1) the association of baseline EZ measures with geographic atrophy (GA) progression and photoreceptor loss and (2) the impact of avacincaptad pegol (ACP), a complement inhibitor, on EZ integrity over the first year of treatment. DESIGN: Post hoc analysis of the phase II/III GATHER 1 and phase III GATHER 2 trials. PARTICIPANTS: Patients 50 years of age and older with non-center point-involving GA in the study eye. METHODS: Spectral-domain OCT images were evaluated using advanced multilayer segmentation with certified reader validation for EZ integrity, measuring total EZ attenuation or loss (EZ to retinal pigment epithelium [RPE] thickness of 0 μm, i.e., total loss of EZ) and partial EZ attenuation or degradation (EZ-RPE thickness of ≤ 20 μm). Geographic atrophy lesion growth was assessed through fundus autofluorescence. MAIN OUTCOME MEASURES: A natural history assessment of progression of GA and total EZ attenuation in sham-treated eyes based on quartiles of baseline EZ measures and the impact of ACP versus sham on progression of total and partial EZ attenuation over 12 months were evaluated. RESULTS: This study included 292 eyes receiving ACP 2 mg and 332 eyes receiving sham therapy. In sham-treated eyes, mean GA growth and progression of total EZ attenuation were substantially greater in higher quartiles of baseline total EZ attenuation and partial EZ attenuation measures over 12 months. ACP 2 mg significantly reduced mean growth in total EZ attenuation by 19.5% (P = .0009) and mean growth in percentage of partial EZ attenuation by 55.3% (P < .0001) versus sham over 12 months. CONCLUSIONS: Greater baseline total and partial EZ attenuation were associated with higher rates of GA growth and progressive EZ loss over time, establishing these EZ measures as important predictors of future GA growth and photoreceptor loss. ACP reduced EZ loss and degradation over 12 months versus sham. Ellipsoid zone measures may enhance identification of patients at high risk of disease progression who would benefit from early therapeutic intervention. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Ehlers JP, Cetin H, Amine R, et al. Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation and Loss in Eyes with Geographic Atrophy. Ophthalmology. 2026. PMID: 42379522. doi:10.1016/j.ophtha.2026.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。